Evidence map›Paper›PMID 36427953›Full record

ArticleInternational review of neurobiology2022

The emerging role of the microbiome in Alzheimer's disease.

Caroline Wasén, Ella Simonsen, Millicent N Ekwudo, Martin R Profant, Laura M Cox

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International review of neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. mSphere · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Caroline WasénAnn Romney Center for Neurologic Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States; Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Ella SimonsenAnn Romney Center for Neurologic Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States; University of Massachusetts, Amherst, MA, United States.
Millicent N EkwudoAnn Romney Center for Neurologic Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States.
Martin R ProfantDepartment of Immunology, University of Toronto, Toronto, ON, Canada.
Laura M CoxAnn Romney Center for Neurologic Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: lcox@bwh.harvard.edu.
University of Toronto · CA

Funding

Investigating the strain-specific role of Bacteroides in the etiology of Alzheimer's diseaseR01AG076008 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI COX, LAURA MICHELLE · 2021 to 2025
$2.2M
Exploring Akkermansia Genomic and Functional Diversity in Neurologic DiseasesR21NS126866 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI COX, LAURA MICHELLE · 2022 to 2022
$472k
NIA NIH HHS R01 AG076008NINDS NIH HHS R21 NS126866
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia and can be influenced by genetic and environmental factors. Recent studies suggest that the intestinal microbiota is altered in AD patients when compared to healthy individuals and may play a role in disease onset and progression. Aging is the greatest risk factor for AD, and age-related changes in the microbiota can affect processes that contribute to cognitive decline. The microbiota may affect AD by modulating peripheral and central immunity or by secreting factors that influence neurogenesis or neuronal cell death. Finally, probiotic and dietary interventions that target the microbiome may have therapeutic potential to prevent or treat AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionGastrointestinal MicrobiomeMicrobiotaAgingHumansAlzheimer's diseaseImmunityMicrobiotaMicrogliaProbiotics

Identifiers

PMID36427953
PMCPMC10170863
OpenAlexW4310461713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.